iosBio Ltd

Bronze Sponsor

iosBio is developing a first-in-class Epstein-Barr virus (EBV) vaccine with the potential to revolutionize EBV prevention. Unlike current vaccine candidates that rely on intramuscular injection and aim to reduce disease severity, iosBio's vaccine is designed to prevent infection and transmission. This is achieved through a unique combination of proprietary technologies:

• OraPro™ Oral Delivery Platform: Enables convenient oral administration, eliciting a robust mucosal immune response at the primary site of EBV infection.
• Enhance Surface Display™ Platform: Engineered for rapid onset of immunity.
• AI-Optimized Antigens: Our AI-assisted design process has produced patented antigens (including gB, gHgL, gHgL-gp42 complex and gp350/220) that generate class-leading antibody responses in preclinical studies.

iosBio's preclinical data demonstrate the potential of this oral EBV vaccine to provide superior protection compared to existing approaches. We are committed to advancing this groundbreaking vaccine through clinical development and establishing a new paradigm in EBV prevention.

website